Astellas Pharma Inc.
ALPMFOTCHealthcare● Active
$14.48
+$0.28(+1.99%)
Market Cap$25.9B
P/E Ratio—
52W High$17.85
52W Low$9.34
Astellas Pharma Inc. (ALPMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALPMF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
$0.15
Est. $0.19 · -20.6%
Revenue
$3.39B
Est. $3.23B · +5.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ALPMF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.31 | — | — | — | $3.51B | — |
| ▼ Q2 FY2026 | Apr 27, 2026 | $0.19 | $0.15 | -20.6% | $3.39B | $3.23B | +5.0% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $0.29 | $0.36 | +22.0% | $3.64B | $3.38B | +7.8% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.14 | $0.26 | +90.9% | $3.49B | $3.24B | +8.0% |
| ▲ Q2 FY2025 | Apr 25, 2025 | $0.14 | $0.28 | +96.3% | $3.06B | $2.95B | +3.8% |
| ▼ Q1 FY2025 | Feb 4, 2025 | $0.00 | -$0.35 | -35867.0% | $3.29B | $2.85B | +15.6% |
| ▼ Q4 FY2024 | Oct 30, 2024 | $0.15 | $0.13 | -11.2% | $3.11B | $2.97B | +4.6% |
| ▲ Q3 FY2024 | Aug 1, 2024 | $0.09 | $0.14 | +59.0% | $2.95B | $2.56B | +15.1% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026Miss
EPS Actual
$0.15
EPS Est.
$0.19
EPS Surpr.
-20.6%
Revenue
$3.39B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$0.36
EPS Est.
$0.29
EPS Surpr.
+22.0%
Revenue
$3.64B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.26
EPS Est.
$0.14
EPS Surpr.
+90.9%
Revenue
$3.49B
Q2 FY2025
Apr 25, 2025Beat
EPS Actual
$0.28
EPS Est.
$0.14
EPS Surpr.
+96.3%
Revenue
$3.06B
Q1 FY2025
Feb 4, 2025Miss
EPS Actual
-$0.35
EPS Est.
$0.00
EPS Surpr.
-35867.0%
Revenue
$3.29B
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
$0.13
EPS Est.
$0.15
EPS Surpr.
-11.2%
Revenue
$3.11B
Q3 FY2024
Aug 1, 2024Beat
EPS Actual
$0.14
EPS Est.
$0.09
EPS Surpr.
+59.0%
Revenue
$2.95B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $22.13 | $22.67 | $23.37 | 1 |
| Q4 FY2026 | $56.20 | $57.57 | $59.36 | 1 |
| Q3 FY2026 | $51.44 | $52.70 | $54.33 | 1 |
| Q2 FY2026 | $48.92 | $50.12 | $51.67 | 1 |
| Q1 FY2026 | $30.04 | $30.77 | $31.72 | 1 |
| Q4 FY2025 | $45.33 | $45.97 | $46.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $513B | $523B | $535B | 1 |
| Q4 FY2026 | $594B | $605B | $620B | 2 |
| Q3 FY2026 | $562B | $572B | $587B | 3 |
| Q2 FY2026 | $551B | $561B | $573B | 4 |
| Q1 FY2026 | $493B | $515B | $530B | 6 |
| Q4 FY2025 | $483B | $530B | $560B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 27, 2026 | -20.6% | $15.60 | $15.60 | +0.00% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +22.0% | $13.67 | $14.90 | +9.00% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +90.9% | $9.54 | $10.46 | +9.64% |
| ▲ Q2 FY2025 | Apr 25, 2025 | +96.3% | $8.87 | $10.12 | +14.09% |
| ▼ Q1 FY2025 | Feb 4, 2025 | -35867.0% | $9.38 | $9.38 | +0.00% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -11.2% | $11.05 | $12.00 | +8.60% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +59.0% | $10.55 | $10.55 | +0.00% |
| ▼ Q2 FY2024 | Apr 25, 2024 | -585.0% | $9.50 | $9.84 | +3.58% |
Q2 FY2026+0.00%
Report Date
Apr 27, 2026
EPS Beat/Miss
-20.6%
Price Before
$15.60
Price After
$15.60
Q1 FY2026+9.00%
Report Date
Feb 4, 2026
EPS Beat/Miss
+22.0%
Price Before
$13.67
Price After
$14.90
Q3 FY2025+9.64%
Report Date
Jul 30, 2025
EPS Beat/Miss
+90.9%
Price Before
$9.54
Price After
$10.46
Q2 FY2025+14.09%
Report Date
Apr 25, 2025
EPS Beat/Miss
+96.3%
Price Before
$8.87
Price After
$10.12
Q1 FY2025+0.00%
Report Date
Feb 4, 2025
EPS Beat/Miss
-35867.0%
Price Before
$9.38
Price After
$9.38
Q4 FY2024+8.60%
Report Date
Oct 30, 2024
EPS Beat/Miss
-11.2%
Price Before
$11.05
Price After
$12.00
Q3 FY2024+0.00%
Report Date
Aug 1, 2024
EPS Beat/Miss
+59.0%
Price Before
$10.55
Price After
$10.55
Q2 FY2024+3.58%
Report Date
Apr 25, 2024
EPS Beat/Miss
-585.0%
Price Before
$9.50
Price After
$9.84
Avg Beat Reaction+8.18%
Avg Miss Reaction+3.04%
Beat Rate4 / 8 quarters
Largest Move+14.09% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALPMF ends December
Astellas Pharma Inc. (ALPMF) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $0.15 — missing the analyst consensus of $0.19 by -20.6%. The next ALPMF earnings date is expected around September 1, 2026.
Each quarter, investors track ALPMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALPMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALPMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALPMF earnings · 5 questionsAstellas Pharma Inc.'s next earnings report is expected around September 1, 2026. ALPMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALPMF historically reports after market close (AMC).
ALPMF earnings datewhen is ALPMF earningsALPMF next earnings datewhen does ALPMF report earningsALPMF earnings calendar
▸ Source: FMP · Astellas Pharma Inc. SEC filings · US GAAP · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026